Economic Atlas
Companies/Lipocine Inc.
Company profile

Lipocine Inc.

NASDAQ: LPCN · Healthcare · Biotechnology
PublicHQ Salt Lake City, UT · Salt LakeCIK 0001535955Reports USD
#804 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
48D
Revenue TTM
$2.0M
Rev growth YoY (TTM)
-45.5%
Net income (FY)
-$9.6M
Employees
14
as of 2026-08-22
Market cap
$17.2M
as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$2.0M$2.0M2025
Net income-$9.6M-$9.6M2025
Operating income-$10.4M-$10.4M2025
Total assets$17.0M$17.0M2025
Liabilities$2.5M$2.5M2025
Equity$14.5M$14.5M2025

Revenue trend

FY2018 – FY2025 · USD
FY18
FY19
FY21
FY22
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2024
By product
Royalty100%
By geography

Not disclosed.

The read

What is Lipocine Inc.’s revenue?

Lipocine Inc. booked $2.0M in FY2025 revenue, contracting 82% year over year — slower than 89% of Healthcare companies we track, at a -487.1% net margin.

Peers · Healthcare
Oramed Pharmaceuticals Inc.61CRapid Dose Therapeutics Corp.38DPressure BioSciences, Inc.——THC Biomed Intl Ltd.——iSpecimen Inc.29DAnteris Technologies Global Corp.32D
Neighbors
Salt Lake →
Extra Space Storage Inc.$129.5M67BZions Bancorporation, National Association$529.0M57CHealthEquity, Inc.$1.3B82B+Merit Medical Systems, Inc.$1.5B83B+Rest Ez Inc.$0——PROG Holdings, Inc.$2.4B72B
Key facts
CEOMahesh V. Patel
SectorHealthcare
IndustryBiotechnology
HeadquartersSalt Lake City, UT
ExchangeNASDAQ: LPCN
Employees14
IPO date2013-10-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.